DB:MM6

Stock Analysis Report

Executive Summary

BioScrip, Inc. provides infusion and home care management solutions in the United States.

Risk Analysis

Does not have meaningful revenue ($735M)



Snowflake Analysis

Slightly overvalued with worrying balance sheet.


Similar Companies

Share Price & News

How has BioScrip's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

-6.3%

MM6

0.06%

DE Healthcare

0.7%

DE Market


1 Year Return

0.5%

MM6

13.5%

DE Healthcare

15.1%

DE Market

Information is not available.

Information is not available.


Shareholder returns

MM6IndustryMarket
7 Day-6.3%0.06%0.7%
30 Day4.4%-0.3%-0.7%
90 Day32.1%6.0%5.9%
1 Year0.5%0.5%15.6%13.5%18.7%15.1%
3 Year-4.1%-4.1%-21.6%-24.4%19.2%8.6%
5 Year-58.0%-58.0%21.0%14.3%39.0%20.1%

Price Volatility Vs. Market

How volatile is BioScrip's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioScrip undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MM6 (€2.38) is trading below our estimate of fair value (€6.29)

Significantly Below Fair Value: MM6 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MM6 is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: MM6 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MM6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MM6 has negative assets, so we can't compare its PB Ratio to the DE Healthcare industry average.


Next Steps

Future Growth

How is BioScrip forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

50.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MM6 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MM6 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MM6 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MM6's revenue (4.9% per year) is forecast to grow slower than the German market (4.9% per year).

High Growth Revenue: MM6's revenue (4.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has BioScrip performed over the past 5 years?

28.9%

Historical annual earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Earnings Trend: MM6 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.9% per year.

Accelerating Growth: Unable to compare MM6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MM6 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-6.8%).


Return on Equity

High ROE: MM6's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is BioScrip's financial position?


Financial Position Analysis

Short Term Liabilities: MM6 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MM6 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MM6 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MM6's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MM6 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MM6 has sufficient cash runway for 1.046239 years if free cash flow continues to grow at historical rates of 33.4% each year.


Next Steps

Dividend

What is BioScrip's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.8%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MM6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MM6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MM6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MM6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MM6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of BioScrip's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Dan Greenleaf (54yo)

2.9yrs

Tenure

US$4,111,309

Compensation

Mr. Daniel E. Greenleaf, also known as Dan, has been the Chief Executive Officer and President at BioScrip, Inc. since September 9, 2016. Mr. Greenleaf has over 21 years of relevant experience in senior le ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: MM6's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

57yo

Average Age

Experienced Board: MM6's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$244,72330 May 19
Teton Advisors, Inc
EntityCompany
Shares150,000
Max PriceUS$1.63
SellUS$3,29430 May 19
Gabelli & Company Investment Advisers, Inc.
EntityCompany
Shares1,800
Max PriceUS$1.83
SellUS$030 May 19
GAMCO Investors, Inc.
EntityCompany
Shares382,623
Max PriceUS$2.00
SellUS$182,76930 May 19
Teton Advisors, Inc
EntityCompany
Shares107,669
Max PriceUS$1.89
BuyUS$030 May 19
GAMCO Investors, Inc.
EntityCompany
Shares727,871
Max PriceUS$2.01
BuyUS$030 May 19
Gabelli & Company Investment Advisers, Inc.
EntityCompany
Shares824,829
Max PriceUS$2.01
BuyUS$1,29615 Mar 19
Gabelli & Company Investment Advisers, Inc.
EntityCompany
Shares400
Max PriceUS$3.27
BuyUS$45,35215 Mar 19
Teton Advisors, Inc
EntityCompany
Shares15,583
Max PriceUS$2.91
SellUS$138,57015 Mar 19
Teton Advisors, Inc
EntityCompany
Shares46,166
Max PriceUS$3.16
SellUS$943,65815 Mar 19
GAMCO Investors, Inc.
EntityCompany
Shares301,732
Max PriceUS$3.43

Ownership Breakdown

Information is not available.


Management Team

  • Vito Ponzio (64yo)

    Chief Administrative Officer & Senior VP

    • Tenure: 0yrs
    • Compensation: US$828.22k
  • Rich Denness

    Senior VP & Chief Commercial Officer

    • Tenure: 1.1yrs
  • Dan Greenleaf (54yo)

    CEO, President & Director

    • Tenure: 2.9yrs
    • Compensation: US$4.11m
  • Bob Roose (61yo)

    Chief Procurement Officer & Senior VP

    • Tenure: 0yrs
    • Compensation: US$552.16k
  • John McMahon (54yo)

    VP, Controller & Chief Accounting Officer

    • Tenure: 0.8yrs
  • Steve Deitsch (46yo)

    Senior VP

    • Tenure: 2.3yrs
    • Compensation: US$1.20m
  • Kathryn Stalmack

    Senior VP

    • Tenure: 4yrs
    • Compensation: US$999.25k
  • Leslie McIntosh

    SVP & Chief Human Resources Officer

    • Tenure: 1.1yrs
  • Harriet Booker (53yo)

    Senior VP & COO

    • Tenure: 1.8yrs
    • Compensation: US$1.07m

Board Members

  • Steve Neumann (51yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$192.25k
  • Michael Bronfein (63yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$206.50k
  • Michael Goldstein (77yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$210.50k
  • Dan Greenleaf (54yo)

    CEO, President & Director

    • Tenure: 2.9yrs
    • Compensation: US$4.11m
  • David Golding (57yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$202.50k
  • R. Pate (64yo)

    Non-Executive Chairman

    • Tenure: 3.2yrs
    • Compensation: US$279.00k
  • Chris Shackelton (39yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$188.50k

Company Information

BioScrip, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioScrip, Inc.
  • Ticker: MM6
  • Exchange: DB
  • Founded: 1996
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$344.912m
  • Listing Market Cap: US$307.145m
  • Shares outstanding: 129.18m
  • Website: https://www.bioscrip.com

Number of Employees


Location

  • BioScrip, Inc.
  • 1600 Broadway
  • Suite 700
  • Denver
  • Colorado
  • 80202
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 1996
MM6DB (Deutsche Boerse AG)YesCommon StockDEEURAug 1996
MM6XTRA (XETRA Trading Platform)YesCommon StockDEEURAug 1996

Biography

BioScrip, Inc. provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/07 21:08
End of Day Share Price2019/08/06 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.